Board summary
Key figures
41,588
Registered population
60.6% aged 18–64
16.2%
Aged 65+
ICB 19.9% · England 17.9%
16.6%
Ethnic minority (non-White)
6.8% Asian · England 9.6%
12.8%
In IMD quintile 1
ICB 17.1% · England 21.0%
~5,052
Core20 residents (est.)
Resident basis; registered basis ~5,320 · see page 3
6,549
Hypertension register
+6.05% in 3 yrs · England +5.60%
335
SMI register
11.8% of Medway (LAD)'s
671
COPD register
Reviews -0.72% in 3 yrs
Forecast to 2030
7,624
Hypertension patients, 2030
+1,075 on today
73.0%
QRISK ≥20% on statins, 2030
+4.19pp over 3 yrs
4.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual review completion fell over three years.
Completion fell 10.9% over 2023 to 2025 (England +4.4%) to 58.1%, leaving about 980 patients unreviewed; this may reflect recall capacity, testable by audit.
SMI blood pressure checks trail England and Medway.
Coverage is 69.6% (England 83.4%; Medway 75.5%), down 0.9 pp over 2023 to 2025, with Apex Medical Centre at 61.1% and Court View Surgery.
Hypertension control improved faster than national and local.
Treatment to threshold rose +12.1% over 2023 to 2025 (England +3.6%; Medway +2.7%) to 66.6%, with under-80 blood pressure control up +13.1%.
Population, age and ethnicity
A younger registered list contrasts with heavy local care home bed capacity
Strood PCN serves 41,588 registered patients. The population is younger than benchmarks: 23.1% are aged 0-17, above Medway (21.6%), the ICB (20.7%) and England (19.6%), while 16.2% are aged 65+, below Medway (17.9%), the ICB (19.9%) and England (17.9%). Census usual residents in associated areas are 83.4% White (Medway 84.3%, the ICB 88.6%, England 81.1%) and 16.6% from ethnic minority backgrounds, including 6.8% Asian and 5.3% Black residents. These residential Census proportions may not match registered patient demographics but provide baseline context for service planning.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Medway (LAD) local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Medway LA) | 1,507 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 75.0% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 53.0% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Medway LA) | 740 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Medway LA) | 19.5 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 share is 12.8% overall but ranges by 30.6 percentage points across practices
Strood PCN’s Core20 share is 12.8%, below Medway (23.1%), England (21.0%) and NHS Kent and Medway ICB (17.1%). The Core20 share spans 30.6 pp across practices: Court View Surgery records 30.6% (3,164 estimated patients), while Riverside Medical Practice and Borstal Village Surgery both record 0.0%. City Way Surgery accounts for 1,176 estimated patients (9.0%) and Apex Medical Centre accounts for 980 (14.7%). Resident estimates (5,052) and practice-derived totals (5,320) use non-additive bases.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
335
SMI register
0.79% recorded prevalence
349
Learning disability register
0.82% recorded prevalence
34
Care homes, 1,025 beds
In the PCN catchment
8.9%
Provide unpaid care
Medway (LAD), Census 2021
Learning disability prevalence is 0.8% (349 patients), above Medway (0.7%), the ICB (0.6%) and England (0.6%). Severe mental illness prevalence is 0.8% (335 patients), below Medway (0.9%), the ICB (0.9%) and England (1.0%). The catchment contains 34 care homes with 1,025 beds, though resident registration is unconfirmed. Crude recorded prevalence differences do not establish unmet need, under-detection, or coding quality.
Severe mental illness: physical health checks
SMI blood pressure checks fell 0.9 pp over 2023 to 2025 (England +4.4 pp) to 69.6% (England 83.4%), reaching 61.1% at Apex Medical Centre, 61.5% at Court View Surgery, and 67.4% at City Way Surgery.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,549
Hypertension register
+6.05%
Register growth, 3 yrs
Medway (LAD) +3.74% · England +5.60%
+7.39pp
BP control, under 80
≤140/90 · +7.68pp aged 80+
+1,075
More patients by 2030
Forecast 7,624 (17.40%)
Hypertension case-finding and control
Recorded hypertension prevalence is 15.5% (6,549 patients), compared to Medway (15.4%) and England (15.2%). Blood pressure treated to target rose +12.1% over 2023 to 2025 (England +3.6%) to 66.6%, trailing England (70.3%). Recent blood pressure readings reach 89.1% (England 90.0%). Blood pressure control under age 80 improved +13.1% (England +3.2%) to 63.8% (England 67.8%), and in ages 80 and over rose +10.9% (England +2.2%) to 78.2% (England 81.2%). Observation periods for current counts are unstated. While blood pressure control is improving faster than nationally, persistent shortfalls against England highlight an opportunity to prioritise titration recall for patients under 80.
Lipids and statins
Lipid-lowering therapy reaches 63.7% of QRISK ≥ 20% patients (England 63.6%), rising +7.0% over 2023 to 2025 (England +6.2%). In diabetes without CVD, uptake is 72.3% (England 73.2%). Observation periods are unstated. Auditing diabetic lipid therapy presents a targeted opportunity where coverage trails national levels.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 68,686 | £1.70 | £1.90 | £1.86 | £116,766 |
| Cardiovascular (all), 2025 | 85,396 | £2.47 | £3.57 | £3.33 | £210,928 |
In 2026, the PCN prescribed 68,686 lipid-regulating items at £1.70 per item (£116,766 total spend), below Medway (£1.87), England (£1.86), and NHS Kent and Medway ICB (£1.90). The PCN spent £10,990 less than at England's unit cost across 68,686 items.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−10.86%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.16%
Asthma prevalence, PCN 3-yr % change
Asthma reviews fell 10.9% over 2023 to 2025 (England +4.4%) to 58.1% (England 65.7%), leaving about 980 of 2,328 registered patients without a recorded review. Recorded COPD prevalence is 1.6% (England 1.9%), falling 6.7% over 2023 to 2025 (England +2.6%), while annual COPD reviews reached 75.4% (England 76.4%). Second-hand smoking status was recorded for 81.9% of asthma patients aged 6-19 (England 78.8%). Observation periods for current registers are unstated.
Cancer register and children's immunisation
The cancer register expanded +16.9% over 2023 to 2025 (England +9.0%) to 1,526 patients (3.6% prevalence, England 3.8%). In Q1 2025/26, age-5 MMR dose 1 coverage was 94.3% (England 91.7%) but dose 2 was 84.3% (England 82.8%), a 10 pp dose drop-off. Pre-school 4-in-1 booster coverage was 80.7%, below the 95.0% target by 14.3 pp. Re-engaging families before school entry is critical to close booster gaps.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
In 2022, 55.6% of staged cancers in NHS Kent and Medway ICB were diagnosed at stage 1 or 2 (England 55.3%), sitting 19.4 pp below the national 75.0% ambition. Reaching 75.0% would require about 1,630 extra early-stage cases a year across the ICB, where the early-stage share rose +2.2 pp between 2013 and 2022. Only 63.6% of registered cancers had a known stage (England 67.0%), meaning staging coverage is incomplete. System staging figures reflect the wider ICB rather than PCN performance. At PCN level, Strood PCN's cancer register expanded +16.9% over 2023 to 2025 (England +9.0%) to 1,526 patients.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026, Medway NHS Foundation Trust achieved 81.6% against the 85.0% 62-day cancer standard, ahead of NHS Kent and Medway Integrated Care Board (75.9%) and England (71.2%), while Maidstone and Tunbridge Wells NHS Trust reached 87.4% and Dartford and Gravesham NHS Trust 63.6%. Medway met the 28-day faster diagnosis standard at 77.8% and 31-day standard at 99.6%. For diagnostics, 6-week waits were 0.0% for CT and 0.7% for MRI, but cardiology echocardiography reached 36.6% (England 28.5%). Provider waits describe system capacity rather than PCN delivery, highlighting where diagnostic delays could affect secondary care workup.
| Pathways within standard (%) | Medway | Maidstone and Tunbridge Wells | Dartford and Gravesham | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 77.77 | 81.78 | 78.14 | 76.78 | 79.32 |
| 31-day treatment (96%) | 99.62 | 98.35 | 97.48 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 81.64 | 87.43 | 63.59 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Medway | Maidstone and Tunbridge Wells | Dartford and Gravesham | England |
|---|---|---|---|---|
| MRI | 0.68 | 0.92 | 0.36 | 21.40 |
| CT | 0.00 | 0.51 | 2.08 | 9.92 |
| Echocardiography | 36.62 | 2.57 | 3.90 | 28.48 |
| Colonoscopy | 1.88 | 19.80 | 0.40 | 30.83 |
| Gastroscopy | 3.32 | 24.03 | 0.00 | 29.02 |
| All 15 DM01 tests | 14.20 | 6.42 | 8.37 | 23.14 |
| Community services activity | Medway residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 43,510 | 254,055 |
| Referrals | 8,580 | 68,085 |
| Patients with a contact | 11,540 | 72,060 |
Community services (residents of Medway), Jun 2026 (provisional). In Jun 2026, 62% of community service contacts with Medway borough residents were for adults aged 65 and over (26,985 of 43,510 contacts). These provisional figures capture local authority resident activity rather than PCN-specific delivery, describing wider borough activity rather than PCN performance.
Practice variation and patient experience
Patient phone access spans 62.7 pp across practices from 23.8% to 86.5%
In 2025/26, overall QOF achievement ranged from 88.8% at Riverside Medical Practice to 95.5% at Court View Surgery (England 92.5%). Vaccination and immunisation achievement spanned 44.3 pp, from 15.8% at City Way Surgery to 60.2% at Court View Surgery (England 55.2%). All-domain personalised care adjustments reached 13.1% at City Way Surgery against 5.3% at Riverside Medical Practice.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Riverside Medical | 84 | 0.0 | 85.6% | 86.2% | 88.3% |
| Borstal Village | 95 | 0.0 | 86.5% | 70.1% | 82.4% |
| Court View Surgery | 105 | 30.6 | 35.0% | 81.0% | 67.3% |
| Apex | 97 | 14.7 | 35.6% | 70.2% | 63.9% |
| City Way Surgery | 134 | 9.0 | 23.8% | 77.6% | 54.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Twelve tracked measures trail England over three years, though blood pressure control improved
Across 2023 to 2025, 12 of 25 tracked measures trail England's three-year change. Annual heart failure reviews fell 10.3% (England +8.7%) to 76.3% (England 78.5%), and asthma reviews fell 10.9% (England +4.4%) to 58.1% (England 65.7%). Physical health monitoring for severe mental illness also declined: BMI recording fell 2.8 pp (England +5.1 pp) and blood pressure checks fell 0.9 pp (England +4.4 pp). Conversely, blood pressure control under 80 rose +13.1% (England +3.2%), and hypertension treated to target rose +12.1% (England +3.6%) to 66.6% (England 70.3%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Asthma reviews
COPD register
Learning disability register
BMI record (SMI)
BP control, under 80
BP control, 80+
Hypertension treated to target
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Medway (LAD) | Asset | PCN | Medway (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 34 (1,025 beds) | n/a | Schools (catchment) | 88 | n/a |
| Children's centres | 5 | 19 | Places of worship | 45 | 110 |
| Libraries | 1 | 9 | Food banks (VCS) | 2 | 6 |
| Homelessness support (VCS) | 3 | 9 | Day centres (VCS) | 14 | 29 |
| Children and young people (VCS) | 22 | 65 | Carers support groups (VCS) | 10 | 22 |
| Primary schools (LA maintained) | 7 | 17 | Primary academies | 21 | 56 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Asthma annual review recall
Asthma reviews fell 10.9% over 2023 to 2025 to 58.1% across 2,328 registered patients (about 980 unreviewed), trailing Medway (62.6%) and England (65.7%). For discussion: practices could run a single-template asthma recall prioritising unreviewed patients, offering after-school or flexible review slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
SMI physical health check outreach
SMI blood pressure checks fell 0.9 pp over 2023 to 2025 to 69.6% across 335 registered patients (Medway 75.5%, ICB 79.7%, England 83.4%), and BMI recording is 69.6% (England 82.1%). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
COPD register validation and case-finding
COPD prevalence is 1.6% (671 patients), below Medway (1.7%), England (1.9%) and the ICB (2.0%), falling 6.7% over 2023 to 2025 (England +2.6%); benchmark gap range is +56 to +117. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Paediatric capacity review (p2) | Aged 0-17 | Medium Term Planning Framework 2026 · Neighbourhood health framework | PCN |
| Targeted Core20 outreach deployment (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall audit (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension titration recall (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall catch-up (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Primary care cancer pathway review (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Telephony and triage workflow review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · SMI physical health check outreach (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN & Practice |
| Option 3 · COPD register validation and case-finding (p12) | COPD register · COPD: QOF prevalence · Registered population | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
